Introduction {#S0001}
============

Gastric cancer is the most commonly diagnosed malignancy and is one of the most frequent causes of cancer mortality worldwide \[[@CIT0001]\]. Although population screening programs in Japan have improved the early detection of gastric cancer and improved patient outcomes, the majority of gastric cancer patients outside Japan are still diagnosed at advanced stages. Advances in chemotherapy and surgical techniques have increased the survival rate of patients with gastric cancer, but the outcome of this common malignancy remains unsatisfactory because of poor understanding of the pathogenesis of gastric cancer and the lack of specific target gene therapy. The pathogenesis of gastric carcinomas is multifactorial, including genetic predisposition and environmental factors. Genetic predisposition is accompanied by several genetic alternations, including tumor suppressor genes, oncogenes, cell adhesion molecules, growth factors, and genetic stability \[[@CIT0002]\]. Therefore, the molecular mechanisms involved in gastric cancer should be understood further and more prognostic markers should be identified to improve prognosis and to provide novel therapeutic targets.

Secreted protein acidic and rich in cysteine (SPARC), also known as osteonectin or BM-40, is a highly conserved multifunctional glycoprotein that belongs to the matricellular class of proteins \[[@CIT0003]\]. Matricellular proteins function as adaptors that mediate cell--extracellular matrix (ECM) interactions and are expressed in tissues undergoing repair or remodeling. The SPARC is involved in regulating cell adhesion, proliferation, migration, and tissue remodeling and is expressed during cell development and processes that require extracellular matrix turnover, such as wound healing and tumor progression \[[@CIT0004], [@CIT0005]\]. The SPARC expression is altered in many cancers. Increased SPARC expression has been observed in melanoma, glioma, colorectal, and breast carcinomas compared to their respective normal tissues \[[@CIT0006]\]. In these tumors, high levels of SPARC are often correlated with enhanced invasion and metastasis \[[@CIT0007]\]. By contrast, increased SPARC expression in ovarian carcinoma cells causes increased tumor cell apoptosis and is inversely correlated with tumor progression *in vivo* \[[@CIT0008]\]. In pancreatic tumors, SPARC expression in cancer cells is limited by promoter hypermethylation, whereas infiltrating stromal cells exhibit increased SPARC expression \[[@CIT0009]\]. Thus, the context of SPARC expression in the microenvironment is critical for understanding its influence on tumor growth and progression. Many studies have recently reported the correlation between SPARC expression and gastric cancer, but their results were inconclusive partially because of the relatively small sample size in each published study. Therefore, we performed a meta-analysis to derive a more precise estimate of the association between SPARC expression and gastric cancer.

Material and methods {#S0002}
====================

Publication search {#S20003}
------------------

We performed a comprehensive search of the literature for abstracts of studies involving human subjects to identify articles regarding the prognostic role of SPARC expression in gastric cancer. Articles from January 1995 to October 2013 in the Medline, Embase, and Wanfang databases were searched using the following key words: "secreted protein, acidic and rich in cysteine", "SPARC", "osteonectin", "BM-40", "gastric carcinoma", "gastric cancer", "overall survival", and "OS". All searched studies were retrieved, and their bibliographies were checked for other relevant studies, which were manually searched to find additional eligible studies.

Information was carefully extracted independently from all eligible publications by two of the authors according to the inclusion criteria. Disagreements were resolved through consensus. The inclusion criteria were as follows: (1) articles dealing with SPARC expression and either the prognostic factors or overall survival (OS) of gastric cancer; (2) articles containing sufficient data that allow estimation of the odds ratio (OR) or relative risk (RR) of OS; (3) articles reported in English or Chinese; and (4) articles published as original research. Reviews, comments, duplicated studies, and articles unrelated to our analysis were excluded. Studies with follow-up periods less than 2 years were also excluded.

The following information was extracted from the included papers: author, publication year, patient\'s racial/ethnic background, tumor stage, number of patients, cell type of SPARC expression, research technique used, and definition of SPARC high expression. Two major groups were created according to the objectives. The first group clarified the association between SPARC expression and the clinicopathologic parameters, including depth of invasion, degree of differentiation, and lymph node involvement. The other group investigated the association between SPARC expression and OS.

Statistical analysis {#S20004}
--------------------

The meta-analysis was performed as previously described \[[@CIT0010]\]. For ease of analysis, the SPARC expression data and the clinicopathologic factors were combined into single categories: high SPARC expression and negative SPARC expression, and low SPARC expression; T1 and T2 stages; T3 and T4 stages; and well differentiated and moderately differentiated. The ORs with 95% CI were used to evaluate the association between SPARC expression and clinicopathologic factors such as tumor differentiation, lymph node involvement, and lymphatic invasion. The survival data were extracted using scanned images of published curves. Differences in SPARC expression and OS were quantified using RR with 95% CI. Heterogeneity across studies was evaluated using a Q test and *p* values. The ORs and RRs were calculated using a random effects model when the *p* values were less than 0.05. Otherwise, a fixed effects model was used. A Begg and Egger funnel plot was used to assess publication bias. Statistical analyses were performed using the Review Manager software. The *p* values were two-sided, with significance at *p* \< 0.05.

Results {#S0005}
=======

Description of studies {#S20006}
----------------------

The results of the search strategy for studies are summarized in [Figure 1](#F0001){ref-type="fig"}. Finally, a total of 10 publications met the criteria for this analysis \[[@CIT0011]--[@CIT0020]\]. The total number of patients was 1417, ranging from 43 to 436 patients per study. The main characteristics of the eligible studies are summarized in [Table I](#T0001){ref-type="table"}. Seven articles dealt with clinicopathologic factors, 6 studies determined the OS, and only three studies reported the association between SPARC expression and clinicopathologic factors without OS analysis. The studies mainly used two methods to evaluate SPARC expression in gastric cancer specimens: immunohistochemistry (IHC) and reverse transcription PCR (RT-PCR).

![Methodological flow diagram of the systematic review](AMS-10-23752-g001){#F0001}

###### 

Main characteristics of the eligible studies

  Study                   Patient\'s country   Year   Tumor stage (UICC)   Mean age \[years\] (range)   Type of gastric cancer                                                                                  Cell type of SPARC expression                     Technique     Number of patients   Survival analysis   Cutoff of SPARC high expression
  ----------------------- -------------------- ------ -------------------- ---------------------------- ------------------------------------------------------------------------------------------------------- ------------------------------------------------- ------------- -------------------- ------------------- ---------------------------------
  Wang \[[@CIT0011]\]     Taiwan               2004   I--IV                61 (35--83)                  Intestinal, diffuse                                                                                     Gastric cancer cells, stroma cells, fibroblasts   IHC, RT-PCR   43                   OS                  Staining index score of ≥ 2
  Li \[[@CIT0017]\]       China                2006   I--IV                59 (ND)                      Adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma                                     Gastric cancer cells, stroma cells                IHC           108                  ND                  Staining index score of ≥ 1
  Franke \[[@CIT0012]\]   Germany              2009   I--IV                64.6 (ND)                    Intestinal, diffuse                                                                                     Gastric cancer cells, stroma cells                IHC, RT-PCR   174                  OS                  Staining index score of ≥ 1
  Zhao \[[@CIT0013]\]     China                2010   I--IV                60 (30--91)                  Papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma   Gastric cancer cells, stroma cells                IHC           436                  OS                  Staining index score of ≥ 4
  Jeung \[[@CIT0014]\]    Korea                2011   I--IV                58 (22--75)                  ND                                                                                                      ND                                                IHC           66                   OS                  Staining index score of ≥ 3
  Han \[[@CIT0015]\]      China                2011   I--IV                61 (35--83)                  Intestinal, diffuse                                                                                     Gastric cancer cells, stroma cells fibroblasts    IHC           80                   ND                  Staining index score of ≥ 4
  Dong \[[@CIT0016]\]     China                2012   I--IV                58 (33--78)                  Intestinal, diffuse                                                                                     Gastric cancer cells, stroma cells                IHC           123                  OS                  Staining index score of ≥ 3
  Wang \[[@CIT0019]\]     China                2012   I--IV                61 (35--83)                  Intestinal, diffuse                                                                                     Stroma cells                                      IHC           80                   ND                  Staining index score of ≥ 3
  Yang \[[@CIT0018]\]     China                2012   I--IV                59 (32--80)                  Intestinal, diffuse                                                                                     Gastric cancer cells, stroma cells, fibroblasts   IHC           80                   ND                  Staining index score of ≥ 4
  Sato \[[@CIT0020]\]     Japan                2013   I--IV                67 (ND)                      Undifferentiated, differentiated                                                                        ND                                                RT-PCR        227                  OS                  ND

ND -- not documented

Correlation of SPARC expression with clinicopathologic parameters {#S20007}
-----------------------------------------------------------------

Six studies assessed the relationship between SPARC phenotype and depth of invasion ([Figure 2](#F0002){ref-type="fig"}). The pooled OR was 1.17 (95% CI: 0.60--2.29, *Z* = 0.47, *p* = 0.64 random effects). The SPARC expression was not significantly correlated with depth of invasion ([Figure 2](#F0002){ref-type="fig"}). The SPARC expression was not significantly correlated with clinicopathologic parameters such as tumor differentiation (pooled OR = 0.59, 95% CI: 0.22--1.58, *Z* = 1.06, *p* = 0.29 random effects) and lymph node metastasis (OR = 0.72, 95% CI: 0.37--1.41, *Z* = 0.96, *p* = 0.34 random effects) ([Figures 3](#F0003){ref-type="fig"} and [4](#F0004){ref-type="fig"}). Moreover, Egger\'s test indicated that these clinicopathologic parameters showed no significant publication bias ([Figure 5](#F0005){ref-type="fig"}).

![Forest plot of odds ratios (ORs) for the association of SPARC expression with depth of invasion](AMS-10-23752-g002){#F0002}
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Effect of SPARC expression on overall survival of gastric cancer {#S20008}
----------------------------------------------------------------

A meta-analysis was performed on six studies that investigated the association between SPARC expression and OS. The pooled RR was calculated using the methods described above. The test for heterogeneity was significant (*p* \< 0.0001); thus, a random effects model was used to calculate the RR. The presence of SPARC expression was correlated with poor OS (pooled RR = 1.78, 95% CI: 1.52--2.09, *Z* = 7.10, *p* = 0.43) ([Figure 6](#F0006){ref-type="fig"}). This finding indicates that SPARC is an independent prognostic factor for gastric cancer. No significant publication bias was detected ([Figure 5](#F0005){ref-type="fig"}).
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Discussion {#S0009}
==========

To the best of our knowledge, the present meta-analysis is the first English language study to systematically determine the association between SPARC expression and gastric cancer survival. The prognostic and predictive significance of SPARC expression in gastric cancer is controversial; for example, Zhao *et al*. \[[@CIT0013]\] found that expression of SPARC in gastric cancer was significantly associated with lymph node and distant metastasis and poor prognosis. However, Wang *et al*. \[[@CIT0019]\] reported that SPARC inhibited the development and progression of gastric cancer; thus, a quantitative meta-analysis of study outcomes is warranted. Our analysis indicated that SPARC expression is significantly associated with OS, which indicates that SPARC is a potential marker for poor gastric cancer prognosis.

Recent studies have shown that SPARC modulates the proliferation, apoptosis, invasion, and angiogenesis of different types of cancers; however, the underlying mechanism remains unknown. Some articles have revealed that SPARC is upregulated in gastric cancer tissues compared with that in normal gastric tissues \[[@CIT0013], [@CIT0017]\]. In our study, the data show that SPARC is not correlated with lymph node metastasis or degree of tumor differentiation. Although deeper invasion was more common in cases with high SPARC expression than in those with negative or low SPARC expression, the differences were not statistically significant. Some studies reported a significant association between SPARC expression and gastric cancer \[[@CIT0011]--[@CIT0013]\], and that SPARC might be considered a new marker for the staging and management of gastric cancer. Our meta-analysis suggests that patients with high expression of SPARC have worse prognosis than those with low expression of SPARC, which suggests that SPARC may be useful as a prognostic indicator. However, our results should be interpreted with extreme caution. Several factors that may influence the conclusion of each included report should also be considered, such as sample size, immunohistochemical staining patterns (membrane versus cytoplasm), and the choice of cutoff scores for positive staining or staining intensity.

This meta-analysis has some limitations. First, the number of included studies is relatively small, with only 1417 cases. Gastric cancer patients received different treatments (perioperative adjuvant therapy or curative surgical resection) and had varying preoperative TNM categories and histologic types. We were unable to assess the potential confounding variables in the individual studies. Second, although immunohistochemistry was the most commonly applied method for detecting SPARC *in situ*, the RT-PCR method was also used to evaluate the expression levels SPARC in tumor tissues. Therefore, the impact of SPARC expression on prognosis in gastric cancer should be further validated. Third, nine of the ten studies in this meta-analysis evaluated patients from Asian populations; thus, more studies should include populations from different ethnicities and regions to confirm our findings. Moreover, the cutoff values were defined differently in the included studies, causing between-study heterogeneity. Thus, we adopted a random effects model and performed subgroup sensitivity analyses to compensate for this limitation.

In conclusion, our results indicate that SPARC expression is not associated with the common clinicopathologic parameters of gastric cancer, such as depth of invasion, tumor differentiation, and lymph node metastasis. However, high SPARC expression is associated with worse outcomes than negative and low SPARC expression, and SPARC is an independent indicator of reduced survival. Further studies on SPARC and its potential as a clinical marker for gastric cancer prognosis are warranted.
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